Drug intelligence / Profile preview

ChondroStem

Development stage: Preclinical
Lead developer: International Stem Cell Corporation
Modality: Stem Cell Therapies → Cell Therapies

Overview

ChondroStem is a cell therapy product developed by International Stem Cell Corp. for the treatment of musculoskeletal and skin diseases, with a primary focus on osteoarthritis. It is classified as a stem cell-based therapy, specifically designed to address cartilage degeneration and joint disorders. The mechanism of action likely involves the use of stem cells to promote regeneration or repair of damaged cartilage tissue in affected joints, although detailed mechanistic data are not publicly available. As of May 2025, ChondroStem's highest reported development status is preclinical, with no regulatory approvals or completed clinical trials disclosed[4].

Brand names: ChondroStem

Beyond the preview

Go deeper on ChondroStem.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ChondroStem.

Explore the full profile